• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion.具有高水平蛋白质分泌的耻垢分枝杆菌突变体对适应性免疫的增强启动作用。
Clin Vaccine Immunol. 2012 Sep;19(9):1416-25. doi: 10.1128/CVI.00131-12. Epub 2012 Jul 11.
2
Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.用 DNA 疫苗接种恒河猴,随后用编码单纯免疫缺陷病毒(SIV)Gag 的腺病毒载体进行加强免疫,可延迟 SIV 经黏膜重复攻击引起的感染。
J Virol. 2019 Oct 15;93(21). doi: 10.1128/JVI.00606-19. Print 2019 Nov 1.
3
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.用减毒活疫苗NYVAC/猴免疫缺陷病毒SIV(gpe)重组疫苗进行黏膜免疫和全身免疫,均可在猕猴的黏膜组织中引发针对gag的CD8(+) T细胞应答。
J Virol. 2002 Nov;76(22):11659-76. doi: 10.1128/jvi.76.22.11659-11676.2002.
4
Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.通过用重组耻垢分枝杆菌致敏快速诱导记忆性CD8 + T淋巴细胞
J Virol. 2007 Jan;81(1):74-83. doi: 10.1128/JVI.01269-06. Epub 2006 Oct 18.
5
Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.重组风疹病毒载体在恒河猴中引发具有细胞毒性潜力的SIV Gag特异性T细胞反应。
Vaccine. 2015 Apr 27;33(18):2167-74. doi: 10.1016/j.vaccine.2015.02.067. Epub 2015 Mar 21.
6
Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.在活风疹载体中表达被广泛中和抗体靶向的完整SIV p27 Gag和HIV gp120工程化外部结构域。
Vaccine. 2017 May 31;35(24):3272-3278. doi: 10.1016/j.vaccine.2017.04.047. Epub 2017 May 5.
7
Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.DNA-SIV与NYVAC-SIV初免/加强免疫方案增强猿猴免疫缺陷病毒(SIV)特异性CD4(+)和CD8(+) T细胞反应
J Immunol. 2001 Dec 15;167(12):7180-91. doi: 10.4049/jimmunol.167.12.7180.
8
A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.一种具有复制能力的腺病毒5型宿主范围突变体-猴免疫缺陷病毒(SIV)重组初免/亚单位蛋白加强疫苗方案可诱导Mamu-A*01恒河猴对显性和隐性表位产生广泛、持久的SIV特异性细胞免疫。
J Immunol. 2003 Apr 15;170(8):4281-9. doi: 10.4049/jimmunol.170.8.4281.
9
CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.CD8 T 细胞在接种 SIV 基因表达的卡介苗(BCG)和痘苗病毒/仙台病毒载体加强疫苗后显示出对高致病性猴免疫缺陷病毒(SIV)的保护作用。
J Virol. 2021 Jan 28;95(4). doi: 10.1128/JVI.01718-20.
10
Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.利用沙门氏菌III型分泌抗原递送系统在恒河猴中引发针对猿猴免疫缺陷病毒的黏膜特异性细胞毒性T淋巴细胞反应。
J Virol. 2003 Feb;77(4):2400-9. doi: 10.1128/jvi.77.4.2400-2409.2003.

引用本文的文献

1
Current efforts and future prospects in the development of live mycobacteria as vaccines.目前开发活结核分枝杆菌疫苗的努力和未来前景。
Expert Rev Vaccines. 2015;14(11):1493-507. doi: 10.1586/14760584.2015.1089175. Epub 2015 Sep 14.

本文引用的文献

1
A novel genetically engineered Mycobacterium smegmatis-based vaccine promotes anti-TB immunity.一种新型基因工程分枝杆菌疫苗促进抗结核免疫。
Expert Rev Vaccines. 2012 Jan;11(1):35-8. doi: 10.1586/erv.11.164.
2
Characterization of the Mycobacterium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research.基于液相色谱-质谱联用蛋白质组学技术的结核分枝杆菌蛋白质组学特性分析:结核病研究的综合资源。
J Proteome Res. 2012 Jan 1;11(1):119-30. doi: 10.1021/pr2007939. Epub 2011 Nov 30.
3
Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway.具有切割或未切割的一般分泌途径信号肽的细菌蛋白。
J Proteomics. 2011 Dec 21;75(2):502-10. doi: 10.1016/j.jprot.2011.08.016. Epub 2011 Sep 5.
4
Oral immunization with recombinant Mycobacterium smegmatis expressing the outer membrane protein 26-kilodalton antigen confers prophylactic protection against Helicobacter pylori infection.用表达26千道尔顿外膜蛋白抗原的重组耻垢分枝杆菌进行口服免疫可对幽门螺杆菌感染提供预防性保护。
Clin Vaccine Immunol. 2011 Nov;18(11):1957-61. doi: 10.1128/CVI.05306-11. Epub 2011 Sep 7.
5
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.一株重组耻垢分枝杆菌诱导针对结核分枝杆菌的强烈杀菌免疫。
Nat Med. 2011 Sep 4;17(10):1261-8. doi: 10.1038/nm.2420.
6
From unwinding to clamping - the DEAD box RNA helicase family.从解旋到夹闭——DEAD 盒 RNA 解旋酶家族。
Nat Rev Mol Cell Biol. 2011 Jul 22;12(8):505-16. doi: 10.1038/nrm3154.
7
Recombinant Mycobacterium smegmatis vaccine candidates.重组耻垢分枝杆菌候选疫苗
Acta Microbiol Immunol Hung. 2011 Mar;58(1):13-22. doi: 10.1556/AMicr.58.2011.1.2.
8
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice.分枝杆菌释放具有活性的膜泡,以 TLR2 依赖的方式在小鼠中调节免疫应答。
J Clin Invest. 2011 Apr;121(4):1471-83. doi: 10.1172/JCI44261.
9
Flow cytometry sorting of recombinant mycobacterial species yields bacterial clones with enhanced insert expression.重组分枝杆菌物种的流式细胞术分选可产生插入片段表达增强的细菌克隆。
Clin Vaccine Immunol. 2011 Jan;18(1):43-9. doi: 10.1128/CVI.00292-10. Epub 2010 Nov 10.
10
Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors.牛分枝杆菌卡介苗宿主菌株中异源HIV-1 gp120基因表达破坏的分子特征:基于分枝杆菌的疫苗载体工程的关键问题。
J Biomed Biotechnol. 2010;2010:357370. doi: 10.1155/2010/357370. Epub 2010 Jun 27.

具有高水平蛋白质分泌的耻垢分枝杆菌突变体对适应性免疫的增强启动作用。

Enhanced priming of adaptive immunity by Mycobacterium smegmatis mutants with high-level protein secretion.

作者信息

Taylor Natalie, Bahunde Faith, Thompson Afton, Yu Jae-Sung, Jacobs William R, Letvin Norm L, Haynes Barton F, Lee Sunhee

机构信息

Duke University School of Medicine, Human Vaccine Institute, Durham, NC, USA.

出版信息

Clin Vaccine Immunol. 2012 Sep;19(9):1416-25. doi: 10.1128/CVI.00131-12. Epub 2012 Jul 11.

DOI:10.1128/CVI.00131-12
PMID:22787192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3428392/
Abstract

Mycobacteria have features that make them attractive as potential vaccine vectors. The nonpathogenic and rapidly growing Mycobacterium smegmatis can express both Mycobacterium tuberculosis antigens and heterologous antigens from other pathogens, and it has been used as a viable vector for the development of live vaccines. In order to further improve antigen-specific immunogenicity of M. smegmatis, we screened a random transposon mutant library for mutants displaying enhanced efficiency of protein secretion ("high secretors") and isolated 61 mutants showing enhanced endogenic and transgenic protein secretion. Sequence analysis identified a total of 54 genes involved in optimal secretion of insert proteins, as well as multiple independent transposon insertions localized within the same genomic loci and operons. The majority of transposon insertions occurred in genes that have no known protein secretion function. These transposon mutants were shown to prime antigen-specific CD8(+) T cell responses better than the parental strain. Specifically, upon introducing the simian immunodeficiency virus (SIV) gag gene into these transposon mutant strains, we observed that they primed SIV Gag-specific CD8(+) T cell responses significantly better than the control prime immunization in a heterologous prime/boost regimen. Our results reveal a dependence on bacterial secretion of mycobacterial and foreign antigens for the induction of antigen-specific CD8(+) T cells in vivo. The data also suggest that these M. smegmatis transposon mutants could be used as novel live attenuated vaccine strains to express foreign antigens, such as those of human immunodeficiency virus type 1 (HIV-1), and induce strong antigen-specific T cell responses.

摘要

分枝杆菌具有一些特性,使其成为有吸引力的潜在疫苗载体。非致病性且生长迅速的耻垢分枝杆菌能够表达结核分枝杆菌抗原以及来自其他病原体的异源抗原,并且已被用作开发活疫苗的可行载体。为了进一步提高耻垢分枝杆菌的抗原特异性免疫原性,我们筛选了一个随机转座子突变体文库,以寻找蛋白质分泌效率增强的突变体(“高分泌者”),并分离出61个显示内源性和转基因蛋白分泌增强的突变体。序列分析共鉴定出54个参与插入蛋白最佳分泌的基因,以及位于同一基因组位点和操纵子内的多个独立转座子插入。大多数转座子插入发生在没有已知蛋白质分泌功能的基因中。这些转座子突变体被证明比亲本菌株能更好地引发抗原特异性CD8(+) T细胞反应。具体而言,在将猿猴免疫缺陷病毒(SIV)gag基因引入这些转座子突变体菌株后,我们观察到在异源初免/加强免疫方案中,它们引发SIV Gag特异性CD8(+) T细胞反应的效果明显优于对照初免免疫。我们的结果揭示了体内诱导抗原特异性CD8(+) T细胞依赖于分枝杆菌和外来抗原的细菌分泌。数据还表明,这些耻垢分枝杆菌转座子突变体可作为新型减毒活疫苗菌株来表达外来抗原,如1型人类免疫缺陷病毒(HIV-1)的抗原,并诱导强烈的抗原特异性T细胞反应。